Medication-Assisted Treatment (MAT)
Medication-assisted treatment (MAT) is the use of medications, in combination with counseling and behavioral therapies, to provide a “whole-patient” approach to the treatment of substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA) and MAT programs are clinically driven and tailored to meet each patient’s needs.
Research shows that a combination of medication and therapy can successfully treat these disorders, and for some people struggling with addiction, MAT can help sustain recovery. MAT is also used to prevent or reduce opioid overdose.
Learn about many of the substance use disorders that MAT is designed to address.
MAT is primarily used for the treatment of addiction to opioids such as heroin and prescription pain relievers that contain opiates. The prescribed medication operates to normalize brain chemistry, block the euphoric effects of alcohol and opioids, relieve physiological cravings, and normalize body functions without the negative and euphoric effects of the substance used.
In 2018, an estimated 2 million people had an opioid use disorder which includes prescription pain medication containing opiates and heroin. MAT has proved to be clinically effective and significantly reduce the need for inpatient detoxification services for these individuals. MAT provides a more comprehensive, individually tailored program of medication and behavioral therapy that addresses the needs of most patients.
The ultimate goal of MAT is full recovery, including the ability to live a self-directed life. This treatment approach has been shown to:
· Improve patient survival
· Increase retention in treatment
· Decrease illicit opiate use and other criminal activity among people with substance use disorders
· Increase patients’ ability to gain and maintain employment
· Improve birth outcomes among women who have substance use disorders and are pregnant
Research also shows that these medications and therapies can contribute to lowering a person’s risk of contracting HIV or hepatitis C by reducing the potential for relapse.